Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries The Gross Law Firm Announces Class Actions on Behalf of Shareholders of KPLT, SAVA and SPPI By: The Gross Law Firm via AccessWire October 17, 2021 at 10:20 AM EDT NEW YORK, NY / ACCESSWIRE / October 17, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.Katapult Holdings, Inc. (NASDAQ:KPLT)Investors Affected : December 18, 2020 - August 10, 2021A class action has commenced on behalf of certain shareholders in Katapult Holdings, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Katapult was experiencing declining e-commerce retail sales and consumer spending, (2) despite Katapult's assertions that it was clear and compelling value proposition to both consumers and merchants, transforming the way nonprime consumers shop for essential goods and enabling merchant access to this underserved segment, Katapult lacked visibility into its consumers' future buying behavior; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.Shareholders may find more information at https://securitiesclasslaw.com/securities/katapult-holdings-inc-loss-submission-form/?id=20490&from=1Cassava Sciences, Inc. (NASDAQ:SAVA)Investors Affected : September 14, 2020 - August 27, 2021A class action has commenced on behalf of certain shareholders in Cassava Sciences, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.Shareholders may find more information at https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=20490&from=1Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)Investors Affected : December 27, 2018 - August 5, 2021A class action has commenced on behalf of certain shareholders in Spectrum Pharmaceuticals, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.Shareholders may find more information at https://securitiesclasslaw.com/securities/spectrum-pharmaceuticals-inc-loss-submission-form/?id=20490&from=1The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@securitiesclasslaw.comPhone: (212) 537-9430Fax: (833) 862-7770 SOURCE: The Gross Law FirmView source version on accesswire.com: https://www.accesswire.com/668464/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-KPLT-SAVA-and-SPPI Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of KPLT, SAVA and SPPI By: The Gross Law Firm via AccessWire October 17, 2021 at 10:20 AM EDT NEW YORK, NY / ACCESSWIRE / October 17, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.Katapult Holdings, Inc. (NASDAQ:KPLT)Investors Affected : December 18, 2020 - August 10, 2021A class action has commenced on behalf of certain shareholders in Katapult Holdings, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Katapult was experiencing declining e-commerce retail sales and consumer spending, (2) despite Katapult's assertions that it was clear and compelling value proposition to both consumers and merchants, transforming the way nonprime consumers shop for essential goods and enabling merchant access to this underserved segment, Katapult lacked visibility into its consumers' future buying behavior; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.Shareholders may find more information at https://securitiesclasslaw.com/securities/katapult-holdings-inc-loss-submission-form/?id=20490&from=1Cassava Sciences, Inc. (NASDAQ:SAVA)Investors Affected : September 14, 2020 - August 27, 2021A class action has commenced on behalf of certain shareholders in Cassava Sciences, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.Shareholders may find more information at https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=20490&from=1Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)Investors Affected : December 27, 2018 - August 5, 2021A class action has commenced on behalf of certain shareholders in Spectrum Pharmaceuticals, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.Shareholders may find more information at https://securitiesclasslaw.com/securities/spectrum-pharmaceuticals-inc-loss-submission-form/?id=20490&from=1The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@securitiesclasslaw.comPhone: (212) 537-9430Fax: (833) 862-7770 SOURCE: The Gross Law FirmView source version on accesswire.com: https://www.accesswire.com/668464/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-KPLT-SAVA-and-SPPI